Eli Lilly and Company (NYSE:LLY) Shares Purchased by Phoenix Wealth Advisors

Phoenix Wealth Advisors lifted its position in Eli Lilly and Company (NYSE:LLY) by 7.4% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 436 shares of the company’s stock after purchasing an additional 30 shares during the period. Phoenix Wealth Advisors’ holdings in Eli Lilly and Company were worth $258,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors also recently added to or reduced their stakes in LLY. Lipe & Dalton acquired a new position in Eli Lilly and Company during the fourth quarter worth $26,000. Thompson Investment Management Inc. acquired a new stake in shares of Eli Lilly and Company in the third quarter valued at about $27,000. Retirement Group LLC raised its position in shares of Eli Lilly and Company by 159.1% in the second quarter. Retirement Group LLC now owns 57 shares of the company’s stock valued at $27,000 after buying an additional 35 shares during the last quarter. Cornerstone Planning Group LLC acquired a new stake in shares of Eli Lilly and Company in the second quarter valued at about $33,000. Finally, Legacy Financial Group LLC acquired a new stake in shares of Eli Lilly and Company in the third quarter valued at about $35,000. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of brokerages have recently commented on LLY. JPMorgan Chase & Co. increased their target price on shares of Eli Lilly and Company from $775.00 to $850.00 and gave the company an “overweight” rating in a research report on Friday, March 15th. Citigroup upped their price objective on shares of Eli Lilly and Company from $675.00 to $895.00 and gave the company a “buy” rating in a report on Tuesday, April 2nd. Wells Fargo & Company upped their price objective on shares of Eli Lilly and Company from $700.00 to $825.00 and gave the company an “overweight” rating in a report on Tuesday, February 6th. Truist Financial reissued a “buy” rating and issued a $850.00 price objective on shares of Eli Lilly and Company in a report on Friday, March 22nd. Finally, BMO Capital Markets upped their price objective on shares of Eli Lilly and Company from $710.00 to $865.00 and gave the company an “outperform” rating in a report on Wednesday, February 7th. Three equities research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company’s stock. According to data from MarketBeat.com, Eli Lilly and Company presently has an average rating of “Moderate Buy” and an average price target of $728.05.

Insider Activity at Eli Lilly and Company

In related news, major shareholder Lilly Endowment Inc sold 78,573 shares of Eli Lilly and Company stock in a transaction on Wednesday, January 31st. The shares were sold at an average price of $648.07, for a total value of $50,920,804.11. Following the transaction, the insider now directly owns 99,333,810 shares in the company, valued at approximately $64,375,262,246.70. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. 0.13% of the stock is currently owned by insiders.

Eli Lilly and Company Stock Performance

Shares of LLY traded down $4.03 during mid-day trading on Wednesday, reaching $746.74. 2,569,799 shares of the company’s stock were exchanged, compared to its average volume of 2,215,511. The company has a debt-to-equity ratio of 1.69, a current ratio of 0.94 and a quick ratio of 0.73. The stock has a market capitalization of $709.52 billion, a PE ratio of 128.75, a price-to-earnings-growth ratio of 1.64 and a beta of 0.34. The business’s fifty day simple moving average is $763.51 and its 200-day simple moving average is $657.01. Eli Lilly and Company has a 52-week low of $367.35 and a 52-week high of $800.78.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings data on Tuesday, February 6th. The company reported $2.49 earnings per share for the quarter, beating analysts’ consensus estimates of $2.30 by $0.19. Eli Lilly and Company had a net margin of 15.36% and a return on equity of 51.22%. The firm had revenue of $9.35 billion for the quarter, compared to analyst estimates of $8.95 billion. During the same period last year, the firm posted $2.09 EPS. Eli Lilly and Company’s quarterly revenue was up 28.1% on a year-over-year basis. On average, equities research analysts expect that Eli Lilly and Company will post 12.52 earnings per share for the current year.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.